Similar articles

• Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.

  van der Voort LF, Gilli F, Bertolotto A, Knol DL, Uitdehaag BM, Polman CH, Killestein J. van der Voort LF, et al. Arch Neurol. 2010 Apr;67(4):402-7. doi: 10.1001/archneurol.2010.21. Epub 2010 Feb 8. Arch Neurol. 2010. PMID: 20142519
• Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.

  Banwell B, Tremlett H. Banwell B, et al. Neurology. 2005 Mar 8;64(5):778-9. doi: 10.1212/01.WNL.0000153532.80277.21. Neurology. 2005. PMID: 15753408 No abstract available.
• Use of interferon-beta in the treatment of multiple sclerosis.

  Derwenskus J, Lublin FD. Derwenskus J, et al. Adv Neurol. 2006;98:257-71. Adv Neurol. 2006. PMID: 16400838 Review. No abstract available.
• Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Sorensen PS, Bertolotto A. Sorensen PS, et al. Neurology. 2007 Oct 9;69(15):1552; author reply 1553. doi: 10.1212/01.wnl.0000285763.31151.a6. Neurology. 2007. PMID: 17923618 No abstract available.
• Treatment of multiple sclerosis with interferon beta 1b.

  Dhib-Jalbut S, McFarland HF. Dhib-Jalbut S, et al. Baillieres Clin Neurol. 1997 Oct;6(3):467-80. Baillieres Clin Neurol. 1997. PMID: 10101584 Review.